Pancreatic AdenocarcinomaCholangiocarcinomaColon Cancer
Investigational drug(s) / intervention(s)
Molecular analyses
Molecular analyses: Search for molecular alterations that correlate with patient prognosis
Study summary
The aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age 18 years or older;
* PS ECOG 0-2;
* Histological diagnosis of cancer of the gastro-enteric district: intestinal, pancreatic, biliary tract neoplasms;
* Radiological evidence of resectable/locally advanced/metastatic disease on the date of the first visit;
* Availability of tumour histological material;
* At least one visit following the first oncological visit.
Exclusion Criteria:
* Absence of histological diagnosis of neoplasm of the gastro-enteric tract;
* Lack of histological specimens on which to perform examinations.
Primary outcome measure(s)
Overall Survival — 48 months The primary objective of the study is to evaluate the probabilitỳ of survival in terms of OS in relation to the expression of specific anatomopathological, immunohistochemical and molecular markers (GATA6, GemPred Molecular Signature and FOLFIRINOX Molecular Signature) present in the tumour tissue of patients with neoplasms of the gastro-enteric district in the setting of resectable/metastatic disease.
Trial sites (1)
Facility
City
Region
Status
Policlinico Universitario Agostino Gemelli
Rome
Lazio
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
